Business Description
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Business History
Price Overview
Last updated: Jun 27, 2026 9:04am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -3.28
Total Equity: $656.16M
Shares: 57,190,000
Total Debt: $35.77M
Cash: $90.81M
EBITDA: -$146.06M
Total Debt: $35.77M
Cash: $90.81M
Revenue: $507.44M
Shares: 57,190,000
Revenue: $507.44M
Revenue: $507.44M
Revenue: $507.44M
Total Equity: $656.16M
Tax Rate: 2.8%
Equity: $656.16M
Total Debt: $35.77M
Cash: $90.81M
Current Liabilities: $101.28M
Long-Term Debt: $35.77M
Total Debt: $35.77M
Total Equity: $656.16M
Shares: 57,190,000
Shares: 57,190,000
CapEx: -$7.67M
Shares: 57,190,000
Stock Price: $143.52
Net Income: -$187.69M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 23, 2026 2:00am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $294.0M | $282.9M | $314.7M | $383.5M | $507.4M |
| Cost of Revenue | $66.6M | $69.0M | $75.6M | $94.0M | $114.2M |
| Gross Profit | $227.4M | $213.9M | $239.1M | $289.5M | $393.2M |
| Operating Expenses | $260.3M | $296.2M | $367.8M | $411.8M | $479.9M |
| Operating Income | -$32.9M | -$82.3M | -$128.7M | -$122.4M | -$86.7M |
| Net Income | -$49.6M | -$99.2M | -$134.7M | -$146.4M | -$187.7M |
| EBITDA | -$1.5M | -$48.8M | -$82.1M | -$95.6M | -$146.1M |
| EPS | $-1.07 | $-2.09 | $-2.78 | $-2.77 | $-3.28 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 23, 2026 2:00am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $100.7M | $119.5M | $93.5M | $169.6M | $90.8M |
| Total Current Assets | $486.1M | $443.9M | $395.5M | $449.8M | $475.0M |
| Total Assets | $1.1B | $1.1B | $940.4M | $974.8M | $893.5M |
| Current Liabilities | $63.4M | $72.4M | $74.0M | $75.1M | $101.3M |
| Long-Term Debt | $280.0M | $281.4M | $282.8M | $0 | $35.8M |
| Total Liabilities | $541.7M | $544.2M | $478.6M | $207.8M | $237.3M |
| Total Equity | $587.2M | $530.0M | $461.8M | $766.9M | $656.2M |
| Retained Earnings | -$365.2M | -$464.4M | -$599.1M | -$745.4M | -$933.1M |
Cash Flow (Annual)
Last updated: Jun 23, 2026 2:00am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $24.7M | -$33.1M | -$57.8M | -$61.3M | -$46.3M |
| Capital Expenditure | -$47.8M | -$30.3M | -$20.2M | -$6.3M | -$7.7M |
| Free Cash Flow | -$23.1M | -$63.3M | -$78.0M | -$67.6M | -$54.0M |
| Acquisitions (net) | $3,000 | $151,000 | $0 | $38,000 | -$12.4M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $4.1M | $18.8M | -$26.1M | $76.2M | -$111.3M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 12:24pm (20h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$796.0M $783.7M – $805.6M
|
$1.0B $1.0B – $1.0B
|
$1.3B $1.3B – $1.3B
|
$1.6B $1.5B – $1.6B
|
| EBITDA |
-$155.3M -$157.2M – -$152.9M
|
-$200.1M -$200.1M – -$200.1M
|
-$256.7M -$262.8M – -$248.2M
|
-$302.7M -$310.0M – -$292.7M
|
| Net Income |
$15.3M $7.6M – $34.6M
|
$92.1M $47.1M – $134.8M
|
$156.4M $149.7M – $161.3M
|
$264.8M $253.4M – $273.1M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 23, 2026 2:00am (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -3.8% | +11.3% | +21.9% | +32.3% |
| Gross Profit Growth | -5.9% | +11.8% | +21.0% | +35.8% |
| Operating Income Growth | -150.4% | -56.4% | +4.9% | +29.1% |
| Net Income Growth | -100.0% | -35.8% | -8.7% | -28.2% |
| EBITDA Growth | -3,208.2% | -68.4% | -16.5% | -52.7% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-28 | Foley Mark J | A-Award | 2,987.00 | $106.52 | $318,175 |
| 2026-05-28 | WEN LEANA | A-Award | 2,987.00 | $106.52 | $318,175 |
| 2026-05-28 | Stapley Marc | A-Award | 2,987.00 | $106.52 | $318,175 |
| 2026-05-28 | WEISNER AIMEE S | A-Award | 2,987.00 | $106.52 | $318,175 |
| 2026-05-28 | Kliman Gilbert H | A-Award | 2,987.00 | $106.52 | $318,175 |
| 2026-05-28 | Hoffmeister David F | A-Award | 2,987.00 | $106.52 | $318,175 |
| 2026-05-28 | Torres Denice | A-Award | 2,987.00 | $106.52 | $318,175 |
| 2026-06-16 | Navratil Tomas | S-Sale | 1,537.00 | $130.68 | $200,855 |
| 2026-05-28 | WEN LEANA | A-Award | 1,878.00 | $0.00 | $0 |
| 2026-05-28 | WEN LEANA | A-Award | 2,987.00 | $53.57 | $160,014 |
| 2026-05-28 | WEISNER AIMEE S | A-Award | 1,878.00 | $0.00 | $0 |
| 2026-05-28 | WEISNER AIMEE S | A-Award | 2,987.00 | $53.57 | $160,014 |
| 2026-05-28 | Torres Denice | A-Award | 1,878.00 | $0.00 | $0 |
| 2026-05-28 | Torres Denice | A-Award | 2,987.00 | $53.57 | $160,014 |
| 2026-05-28 | Foley Mark J | A-Award | 1,878.00 | $0.00 | $0 |
| 2026-05-28 | Foley Mark J | A-Award | 2,987.00 | $53.57 | $160,014 |
| 2026-05-28 | Hoffmeister David F | A-Award | 1,878.00 | $0.00 | $0 |
| 2026-05-28 | Hoffmeister David F | A-Award | 2,987.00 | $53.57 | $160,014 |
| 2026-05-28 | Kliman Gilbert H | A-Award | 1,878.00 | $0.00 | $0 |
| 2026-05-28 | Kliman Gilbert H | A-Award | 2,987.00 | $53.57 | $160,014 |
Narrative Economics
market-narrative step).